Novartis out-licenses three COPD products in the US

Novartis out-licenses three COPD
products in the US

December 21, 2016

Novartis US announced this morning a licensing agreement with Sunovion Pharmaceuticals
Inc. (Sunovion) for the US commercial rights to its COPD treatments Utibron(TM) Neohaler®,
Seebri(TM) Neohaler® and Arcapta® Neohaler®. This deal is specific to the US only and has
no implications outside this market. Novartis will continue to manufacture these medicines for
Sunovion.

The decision was taken after carefully considering the unique and dynamic aspects of the US
COPD marketplace, as well as the model required to successfully navigate a highly
competitive environment with associated market access challenges. This approach will allow
Novartis in the US to focus its resources and attention on other US launch brands, including
Cosentyx® and Entresto®. 

With kind regards
Novartis International AG
Investor Relations